Marshall Wace
VRDN icon

Marshall Wace’s Viridian Therapeutics VRDN Stock Holding History

Marshall Wace’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-269,587
Closed -$5.27M – 3797
2026
Q1 		$5.27M Sell
269,587
-1,106,152
-80% -$32.9M 0.01% 1279
2025
Q4 		$42.8M Buy
1,375,739
+506,551
+58% +$13.9M 0.04% 385
2025
Q3 		$18.8M Sell
869,188
-338,683
-28% -$6.11M 0.02% 679
2025
Q2 		$16.9M Buy
1,207,871
+123,831
+11% +$1.68M 0.02% 649
2025
Q1 		$14.6M Buy
+1,084,040
New +$18.5M 0.02% 623
2024
Q4 		– Sell
-684,799
Closed -$15.6M – 3041
2024
Q3 		$15.6M Buy
684,799
+611,825
+838% +$10M 0.02% 593
2024
Q2 		$949K Sell
72,974
-5,727
-7% -$79.3K ﹤0.01% 1715
2024
Q1 		$1.38M Sell
78,701
-222,588
-74% -$4.32M ﹤0.01% 1524
2023
Q4 		$6.56M Sell
301,289
-661,204
-69% -$10.4M 0.01% 818
2023
Q3 		$14.8M Buy
962,493
+311,314
+48% +$5.94M 0.03% 519
2023
Q2 		$15.5M Buy
651,179
+21,859
+3% +$561K 0.03% 574
2023
Q1 		$16M Buy
629,320
+17,863
+3% +$573K 0.03% 540
2022
Q4 		$17.9M Buy
611,457
+2,795
+0.5% +$64.4K 0.04% 496
2022
Q3 		$12.5M Buy
608,662
+163,863
+37% +$2.95M 0.03% 721
2022
Q2 		$5.14M Buy
444,799
+427,236
+2,433% +$5.74M 0.01% 1316
2022
Q1 		$326K Sell
17,563
-70,842
-80% -$1.36M ﹤0.01% 2943
2021
Q4 		$1.75M Buy
+88,405
New +$1.65M ﹤0.01% 2123

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marshall Wace's VRDN Position: Q2 2026 in Review

Marshall Wace sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 269,587 shares — an estimated $5.27M sold.

Marshall Wace first reported a position in VRDN in Q4 2021 and held it in 17 quarters. The position peaked at $42.8M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Marshall Wace reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 269,587 Viridian Therapeutics shares in Q2 2026, an estimated $5.27M.
  • Marshall Wace first reported a position in Viridian Therapeutics in Q4 2021 and held it in 17 quarters.
  • Marshall Wace's Viridian Therapeutics position peaked at $42.8M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.